Questcor's (NASDAQ:QCOR) flagship drug, Acthar, has been around for over 60 years. Despite its age, the company discovered a way to breathe new life into sales of this old drug. So, why does this remain one of the most controversial companies in the health care space today? In this video, Motley Fool health care bureau chief Brenton Flynn takes us through some of his likes and dislikes with Questcor.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The pros and cons of this controversial biotech.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
Should You Buy Johnson & Johnson Stock Before July 16?
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash
Most Investors Are Not Ready for What's About to Happen
This Stock Has Increased 4,720%: Here's Why It's Still a Buy
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.